GTHP OTC
Guided Therapeutics, Inc.
1W: -11.3%
1M: -12.0%
3M: -21.4%
YTD: -59.3%
1Y: -18.5%
3Y: +46.7%
5Y: -60.4%
$0.22
-0.03 (-11.25%)
Weekly Expected Move ±26.5%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$21.2M
52W Range0.15-0.54
Volume18,300
Avg Volume19,065
Beta0.69
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMark L. Faupel
Employees3
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-01-08
Websiteguidedinc.com
5835 Peachtree Corners East
Peachtree Corners, GA 30092
US
Peachtree Corners, GA 30092
US
770 242 8723
About Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Imhoff John E | C-Conversion | 157,417 | $0.07 | 2026-03-31 |
| Imhoff John E | C-Conversion | 157,417 | $0.07 | 2026-03-31 |
| Blumberg Richard P. | J-Other | 352,000 | — | 2026-03-26 |
| Blumberg Richard P. | J-Other | 19,038 | — | 2026-03-26 |
| Blumberg Richard P. | J-Other | 1,040,000 | — | 2026-03-26 |